A Phase 1, 2-Part, Multicenter, Open-label, 3-Arm Study to Determine the effect of Enasidenib (CC-90007) on the Pharmacokinetics of Single Doses of Caffeine, Dextromethorphan, Flurbiprofen, Midazolam, Omeprazole, Digoxin, Rosuvastatin, and Pioglitazone in Subjects with Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation.

  • Wei, Andrew (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Project Manager)

Project: Research

StatusActive
Effective start/end date12/10/1812/10/23